We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Q1 Earnings In Line With Estimates, Revenues Top
Read MoreHide Full Article
Agilent Technologies’ (A - Free Report) fiscal first-quarter 2020 earnings of 81 cents per share were in line with the Zacks Consensus Estimate. The bottom line decreased 9% sequentially but increased 7% year over year.
Fiscal first-quarter 2020 revenues of $1.36 billion increased 5.7% year over year (up 2.4% on a core basis). Also, the reported revenues — which came in above management’s guided range of $1.340-$1.355 billion — surpassed the Zacks Consensus Estimate by 0.2%.
The year-over-year revenue growth was driven by strength in all revenue segments.
Agilent was optimistic about the acquisition of BioTek Instruments, Inc., a provider of life science instrumentation. This deal will likely expand the company’s presence in the life science research space. It will further strengthen Agilent’s offerings related to live cell analysis, as these product lines aid in quantification of biomolecules, biomolecular interactions and cellular structure.
However, management expects delays in new equipment purchases in the near term. In addition, it expects a slower uptake of consumables and services due to reduced number of selling days resulting from the extension of Lunar New Year, including other operational factors.
Revenues by Segment
Agilent has three reporting segments — Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
In the reported quarter, LSAG was the largest contributor to total revenues. The segment accounted for $638 million or 47% of its total revenues, reflecting a 5% increase from the prior-year quarter. The strong performance of the company’s biopharma and cell analysis business aided the results.
Revenues from ACG came in at $470 million, accounting for 35% of total revenues. The reported figure reflects a 6% year-over-year increase, driven by growth across all regions and market segments.
Revenues from DGG came in at $249 million, accounting for the remaining 18% of total revenues. The segment’s revenues were up 6% from the year-ago quarter.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Gross margin in the quarter was 53.3%, down 180 basis points (bps) year over year. The decrease was due to an unfavorable product mix.
Operating expenses (research & development as well as selling, general & administrative) were $508 million, 11.2% higher than the year-ago quarter.
As a result, adjusted operating margin was 15.8%, down 370 bps from the year-ago quarter.
Balance Sheet
At the end of the fiscal first quarter, inventories totaled $706 million, up from $679 million in the prior quarter. Agilent’s long-term debt was $1.79 billion at the end of the quarter. Cash and cash equivalents were $1.23 billion compared with $1.38 billion in fiscal fourth-quarter 2019.
Guidance
Agilent provided guidance for the fiscal second quarter and 2020.
For the fiscal second quarter, the company expects revenues between $1.28 billion and $1.32 billion, and earnings per share in the range of 72-76 cents. The Zacks Consensus Estimate for revenues and earnings per share is pegged at $1.33 billion and 78 cents, respectively.
For fiscal 2020, Agilent maintained its revenue guidance in the range of $5.50-$5.55 billion, indicating core growth of 4-5%. Non-GAAP earnings are projected in the range of $3.38-$3.43 per share.
The Zacks Consensus Estimate for earnings is pegged at $3.41 per share and the same for revenues is $5.53 billion.
Long-term earnings growth for Itron, Splunk, and Teradyne is currently projected at 25%, 31.2% and 13.2%, respectively.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Agilent (A) Q1 Earnings In Line With Estimates, Revenues Top
Agilent Technologies’ (A - Free Report) fiscal first-quarter 2020 earnings of 81 cents per share were in line with the Zacks Consensus Estimate. The bottom line decreased 9% sequentially but increased 7% year over year.
Fiscal first-quarter 2020 revenues of $1.36 billion increased 5.7% year over year (up 2.4% on a core basis). Also, the reported revenues — which came in above management’s guided range of $1.340-$1.355 billion — surpassed the Zacks Consensus Estimate by 0.2%.
The year-over-year revenue growth was driven by strength in all revenue segments.
Agilent was optimistic about the acquisition of BioTek Instruments, Inc., a provider of life science instrumentation. This deal will likely expand the company’s presence in the life science research space. It will further strengthen Agilent’s offerings related to live cell analysis, as these product lines aid in quantification of biomolecules, biomolecular interactions and cellular structure.
However, management expects delays in new equipment purchases in the near term. In addition, it expects a slower uptake of consumables and services due to reduced number of selling days resulting from the extension of Lunar New Year, including other operational factors.
Revenues by Segment
Agilent has three reporting segments — Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
In the reported quarter, LSAG was the largest contributor to total revenues. The segment accounted for $638 million or 47% of its total revenues, reflecting a 5% increase from the prior-year quarter. The strong performance of the company’s biopharma and cell analysis business aided the results.
Revenues from ACG came in at $470 million, accounting for 35% of total revenues. The reported figure reflects a 6% year-over-year increase, driven by growth across all regions and market segments.
Revenues from DGG came in at $249 million, accounting for the remaining 18% of total revenues. The segment’s revenues were up 6% from the year-ago quarter.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
Operating Results
Gross margin in the quarter was 53.3%, down 180 basis points (bps) year over year. The decrease was due to an unfavorable product mix.
Operating expenses (research & development as well as selling, general & administrative) were $508 million, 11.2% higher than the year-ago quarter.
As a result, adjusted operating margin was 15.8%, down 370 bps from the year-ago quarter.
Balance Sheet
At the end of the fiscal first quarter, inventories totaled $706 million, up from $679 million in the prior quarter. Agilent’s long-term debt was $1.79 billion at the end of the quarter. Cash and cash equivalents were $1.23 billion compared with $1.38 billion in fiscal fourth-quarter 2019.
Guidance
Agilent provided guidance for the fiscal second quarter and 2020.
For the fiscal second quarter, the company expects revenues between $1.28 billion and $1.32 billion, and earnings per share in the range of 72-76 cents. The Zacks Consensus Estimate for revenues and earnings per share is pegged at $1.33 billion and 78 cents, respectively.
For fiscal 2020, Agilent maintained its revenue guidance in the range of $5.50-$5.55 billion, indicating core growth of 4-5%. Non-GAAP earnings are projected in the range of $3.38-$3.43 per share.
The Zacks Consensus Estimate for earnings is pegged at $3.41 per share and the same for revenues is $5.53 billion.
Zacks Rank and Other Stocks to Consider
Currently, Agilent has a Zacks Rank #2 (Buy). Other top-ranked stocks in the broader technology sector include Itron, Inc. (ITRI - Free Report) , Splunk Inc. and Teradyne (TER - Free Report) , each carrying a Zacks Rank #2.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth for Itron, Splunk, and Teradyne is currently projected at 25%, 31.2% and 13.2%, respectively.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>